Clinical Trials · NCT00234520

A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide

Name: A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/AOctreotide Lanreotide

Phase: N/A
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 225
Start date: May 2003
Locations: 33 sites, 10 countries
Primary endpoint: Assessment of the risk of new or worsening valvular regurgitation in any valve by echocardiography at baseline & 12 months

View Octreotide compound reference